Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Calidi Biotherapeutics ( (CLDI) ) has issued an update.
On February 6, 2026, Calidi Biotherapeutics, Inc. posted an updated corporate presentation on its website and furnished the same materials in connection with a Form 8-K filing. The company emphasized that the information was provided under Regulation FD on a furnished, not filed, basis, limiting its treatment under U.S. securities laws and clarifying that it would not be incorporated into other securities filings unless specifically referenced.
The most recent analyst rating on (CLDI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Neutral.
The score is held down primarily by persistent losses and significant cash burn with no revenue base, despite improved leverage and positive equity. Technicals also remain broadly bearish (below key moving averages and negative MACD), while corporate events provide a modest offset through financing and encouraging preclinical progress. Valuation contributes little given the negative P/E and no dividend yield.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics, Inc. is a biotechnology company. It operates in the life sciences sector and is focused on developing therapeutic products, although this filing does not specify particular products, services or target markets.
Average Trading Volume: 87,849
Technical Sentiment Signal: Sell
Current Market Cap: $6.18M
For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.